Zimmer Biomet Holdings Dirección

Dirección controles de criterios 2/4

Zimmer Biomet Holdings' El consejero delegado es Ivan Tornos , nombrado en Mar 2021, tiene un mandato de 2.75 años. la remuneración anual total es $6.44M , compuesta por 12.8% salario y 87.2% primas, incluidas acciones y opciones de la empresa. posee directamente 0.008% de las acciones de la empresa, por valor de MX$35.67M . La antigüedad media del equipo directivo y del consejo de administración es de 4.4 años y 9 años respectivamente.

Información clave

Ivan Tornos

Chief Executive Officer (CEO)

US$10.2m

Compensación total

Porcentaje del salario del CEO	9.5%
Permanencia del CEO	3.1yrs
Participación del CEO	0.01%
Permanencia media de la dirección	4.3yrs
Promedio de permanencia en la Junta Directiva	9.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ivan Tornos en comparación con los beneficios de Zimmer Biomet Holdings?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$10m	US$969k	US$1b
Sep 30 2023	n/a	n/a	US$474m
Jun 30 2023	n/a	n/a	US$506m
Mar 31 2023	n/a	n/a	US$450m
Dec 31 2022	US$6m	US$823k	US$290m
Sep 30 2022	n/a	n/a	US$366m
Jun 30 2022	n/a	n/a	US$334m
Mar 31 2022	n/a	n/a	US$325m
Dec 31 2021	US$5m	US$731k	US$445m
Sep 30 2021	n/a	n/a	US$834m
Jun 30 2021	n/a	n/a	US$914m
Mar 31 2021	n/a	n/a	US$563m
Dec 31 2020	US$4m	US$730k	-US$11m
Sep 30 2020	n/a	n/a	-US$152m
Jun 30 2020	n/a	n/a	US$37m
Mar 31 2020	n/a	n/a	US$377m
Dec 31 2019	US$4m	US$700k	US$1b
Sep 30 2019	n/a	n/a	-US$90m
Jun 30 2019	n/a	n/a	-US$359m
Mar 31 2019	n/a	n/a	-US$308m
Dec 31 2018	US$4m	US$113k	-US$379m

Compensación vs. Mercado: Ivan($USD10.19M) está por encima de la media de empresas de tamaño similar en el mercado MX ($USD5.73M).

Compensación vs. Ingresos: Ivanha aumentado más de un 20% en el último año.

CEO

Ivan Tornos (48 yo)

3.1yrs

Permanencia

US$10,191,476

Compensación

Mr. Ivan Tornos serves as Independent External Director at PHC Holdings Corporation since September 03, 2021. He joined PHC Holdings Corporation on September 03, 2021. Mr. Tornos serves as Chief Operating...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ivan Tornos	COO, President	3.1yrs	US$10.19m	0.013% $ 55.5m
Suketu Upadhyay	CFO and Executive VP of Finance	4.8yrs	US$10.38m	0.010% $ 43.1m
Chad Phipps	Senior VP	16.9yrs	US$2.87m	0.024% $ 102.1m
Sang Yi	President of Asia Pacific	8.8yrs	US$3.38m	0.0089% $ 37.7m
Wilfred van Zuilen	Group President of Europe	2.8yrs	US$3.42m	0.0035% $ 14.9m
Paul Stellato	VP, Controller & Chief Accounting Officer	1.9yrs	sin datos	0.00046% $ 2.0m
Nitin Goyal	Chief Science	2.8yrs	sin datos	sin datos
Zeeshan Tariq	Senior VP & Chief Information Officer	7.8yrs	sin datos	sin datos
Keri Mattox	SVP and Chief Communications & Administration Officer	4.3yrs	sin datos	sin datos
Zachary Weiner	Director of Investor Relations	no data	sin datos	sin datos
Angela Main	Senior VP	8.8yrs	sin datos	sin datos
Lori Winkler	Senior VP & Chief Human Resources Officer	3.2yrs	sin datos	0.0016% $ 6.9m

4.3yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: ZBH *El equipo directivo de la empresa se considera experimentado (4.4 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ivan Tornos	COO, President	less than a year	US$10.19m	0.013% $ 55.5m
Christopher Begley	Independent Chairman of the Board	11.8yrs	US$378.84k	0.0017% $ 7.3m
Betsy Bernard	Independent Director	15.3yrs	US$340.26k	0.0026% $ 10.9m
Robert Hagemann	Independent Director	16.1yrs	US$358.20k	0.0019% $ 8.3m
Michael Michelson	Independent Director	9.3yrs	US$318.84k	0.0016% $ 7.0m
Arthur Higgins	Independent Director	17.2yrs	US$347.75k	0.0016% $ 7.0m
Louis Shapiro	Director	less than a year	sin datos	sin datos
Maria Hilado	Independent Director	5.7yrs	US$314.44k	0.00080% $ 3.4m
Michael Farrell	Independent Director	9.3yrs	US$344.10k	0.00097% $ 4.1m
Sreelakshmi Kolli	Independent Director	3.2yrs	US$382.35k	0.00049% $ 2.1m
Syed Jafry	Independent Director	5.7yrs	US$367.52k	0.0020% $ 8.4m

9.3yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de ZBH * se considera experimentada (9 años de antigüedad promedio).

Zimmer Biomet Holdings Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Zimmer Biomet Holdings, Inc., Annual General Meeting, May 10, 2024

Zimmer Biomet Holdings, Inc. Announces Appointment of Louis A. Shapiro to Board of Directors

Independent Director recently bought Mex$1.9m worth of stock

Zimmer Biomet Holdings, Inc. Announces CEO Changes

Insufficient new directors

Insufficient new directors

Recent updates

Zimmer Biomet Holdings, Inc. to Report Q1, 2024 Results on May 02, 2024

Zimmer Biomet Holdings, Inc., Annual General Meeting, May 10, 2024

Upcoming dividend of US$0.24 per share

Fourth quarter dividend of US$0.24 announced

Full year 2023 earnings released: EPS: US$4.91 (vs US$1.39 in FY 2022)

Fourth quarter dividend of US$0.24 announced

Zimmer Biomet Holdings, Inc. Announces U.S. Food and Drug Administration (FDA) 510(K) Clearance of the Rosa® Shoulder System for Robotic-Assisted Shoulder Replacement Surgery

Zimmer Biomet Holdings, Inc. Announces Quarterly Cash Dividend for the First Quarter of 2024, Payable on or About April 30, 2024

Zimmer Biomet Holdings, Inc. Showcases Latest Innovations Across Comprehensive Portfolio at AAOS 2024 Annual Meeting

Zimmer Biomet Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Zimmer Biomet Holdings, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Zimmer Biomet Holdings, Inc. Announces Appointment of Louis A. Shapiro to Board of Directors

Zimmer Biomet Holdings, Inc. Approves Cash Dividend for the Fourth Quarter of 2023, Payable on or About January 31, 2024

Third quarter 2023 earnings released: EPS: US$0.78 (vs US$0.93 in 3Q 2022)

Zimmer Biomet Holdings, Inc. Updates Revenue Guidance for the Year Ending December 31, 2023

Zimmer Biomet Holdings, Inc. Updates Revenue Guidance for the Year Ending December 31, 2023

Zimmer Biomet Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Upcoming dividend of US$0.24 per share at 0.8% yield

Independent Director recently bought Mex$1.9m worth of stock

Zimmer Biomet Holdings, Inc. Announces Quarterly Dividend for Third Quarter of 2023, Payable on or about October 31, 2023

Zimmer Biomet Holdings, Inc. Announces CEO Changes

Second quarter 2023 earnings released: EPS: US$1.01 (vs US$0.73 in 2Q 2022)

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year 2023

Zimmer Biomet Holdings, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Upcoming dividend of US$0.24 per share at 0.7% yield

Insufficient new directors

Insufficient new directors

Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2023, Payable on July 31, 2023

First quarter 2023 earnings released: EPS: US$1.11 (vs US$0.35 in 1Q 2022)

Upcoming dividend of US$0.24 per share at 0.8% yield

Full year 2022 earnings released: EPS: US$1.39 (vs US$2.13 in FY 2021)

Insufficient new directors

Full year 2022 earnings released: EPS: US$1.39 (vs US$1.93 in FY 2021)

Zimmer Biomet Holdings, Inc. Reports Unaudited Impairment Charges for the Fourth Quarter Ended December 31, 2022

Zimmer Biomet Holdings, Inc. to Report Q4, 2022 Results on Feb 03, 2023

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) entered into a definitive agreement to acquire Embody, Inc. for approximately $300 million.

Insufficient new directors

Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2022, Payable on or About January 31, 2023

Insufficient new directors

Zimmer Biomet Holdings, Inc. Expands Persona(R) Knee System Portfolio with FDA Clearance of Persona(R) Osseoti(R) Keel Tibia for Cementless Knee Replacement

Insufficient new directors

Zimmer Biomet Holdings, Inc. Announces One-Year Data from mymobility® Clinical Study at 2022 AAHKS Annual Meeting

Third quarter 2022 earnings released: EPS: US$0.93 (vs US$0.70 in 3Q 2021)

Zimmer Biomet Holdings, Inc. Updates Financial Guidance for the Year Ending December 31, 2022

Zimmer Biomet Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Upcoming dividend of US$0.24 per share

Zimmer Biomet Holdings, Inc. Receives FDA Clearance for Identity(TM) Shoulder System for Shoulder Replacement

Zimmer Biomet Holdings, Inc Approves Quarterly Cash Dividend, Payable on or About October 31, 2022

Second quarter 2022 earnings released: EPS: US$0.73 (vs US$0.68 in 2Q 2021)

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year Ending December 31, 2022

Zimmer Biomet Holdings, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Upcoming dividend of US$0.24 per share

Now 20% undervalued after recent price drop

Zimmer Biomet Holdings, Inc. Appoints Keri P. Mattox as Chief Communications and Administration Officer

Zimmer Biomet Holdings, Inc. Approves Quarterly Dividend for Second Quarter of 2022, Payable on or About July 29, 2022

Zimmer Biomet Holdings, Inc. Debuts First-Of-Its-Kind Artificial Intelligence Capabilities for Omni™ Suite Intelligent Operating Room

Now 20% undervalued

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year Ending December 31, 2022

First quarter 2022 earnings released: EPS: US$0.93 (vs US$0.95 in 1Q 2021)

Insufficient new directors

Extremity Medical, LLC Files Patent Infringement Lawsuit Against Nextremity Solutions, Zimmer Biomet Holdings, Inc. and Zimmer, Inc

Zimmer Biomet Holdings, Inc. to Report Q1, 2022 Results on May 03, 2022

Upcoming dividend of US$0.24 per share

Zimmer Biomet Holdings, Inc., Annual General Meeting, May 16, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Zimmer Biomet Holdings, Inc. Provides Earnings Guidance for the Full Year Ending December 31, 2022

Insufficient new directors

Group President of Asia Pacific recently sold Mex$7.4m worth of stock

Upcoming dividend of US$0.24 per share